Kaleido Biosciences ran COVID-19 clinical trials of KB109 without required IND, FDA says.
What happened
FDA inspected Kaleido from February 24 to March 3, 2021, as sponsor of two clinical investigations of KB109 in non-hospitalized patients with mild-to-moderate COVID-19. FDA found Kaleido initiated and conducted Protocols K031-120 and K032-120 without submitting an IND (an investigational new drug application) or having one in effect; 350 subjects were randomized in K031-120 and 49 in K032-120. Kaleido argued KB109 was a food, but FDA concluded the study endpoints showed KB109 was intended to treat or mitigate COVID-19 and was therefore a drug.
What FDA found
Kaleido started Protocols K031-120 and K032-120 without submitting an IND or having one in effect.
21 CFR 312.20(a), 312.20(b), 312.40(a)FDA determined KB109 was intended to treat or mitigate COVID-19 in the studies, so it was a drug requiring an IND rather than a food.
FD&C Act section 201(g)(1) [21 U.S.C. 321(g)(1)]
What FDA wants
Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations. If Kaleido believes it complied, include its reasoning and supporting information.
Who should pay attention
- sponsors running COVID-19 drug trials
- clinical trial sites enrolling subjects
- companies classifying products as food, medical food, or drug
This is a summary. Read the original letter on fda.gov.